A total of 485 employees are to be laid off at a Sterling Winthrop research facility in Pennsylvania, USA. The lay-offs are being made by Sanofi, which acquired the SW unit from Eastman Kodak as part of its purchase of the Sterling Winthrop prescription drugs business (Marketletters passim), Hafslund Nycomed, which acquired Sterling's diagnostics imaging business from Sanofi shortly after the latter's acquisition of SW (Marketletters passim), and two divisions of Kodak, which is leasing the facility to Sanofi for one year.
A specific breakdown of the redundancies in relation to each company was not given, but a US spokesperson for Sanofi told the Marketletter that Sanofi is retaining 475 staff at the site, which was more than originally thought.
The majority of the redundancies will be among the basic discovery scientists and support staff. Sanofi has a basic discovery unit in France and does not need to run this operation in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze